The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: A case-crossover study

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 9, 2011, Pages 914-921

  Kilpatrick, Ryan D ^a   Danese, Mark D ^b   Belozeroff, Vasily ^a   Smirnakis, Karen ^a   Goodman, William G ^a   Rothman, Kenneth J ^c  

^a AMGEN INC   (United States)

^b Outcomes Insights Inc   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

Author keywords

Case crossover; Dialysis; Hypercalcemia; Hyperphosphatemia; Nephrology; Vitamin D

Indexed keywords

CALCIUM; PHOSPHORUS; VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATASEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; RENAL DIALYSIS; VITAMIN D;

EID: 80052370806     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2183     Document Type: Article

References (19)

1. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006; 47(1): 149-156.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15(8): 2208-2218.
3. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342(20): 1478-1483.
4. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70(4): 771-780.
5. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52(3): 519-530.
6. Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol 2009; 5(1): 24-33.
7. Bhan I, Thadhani R. Vitamin D therapy for chronic kidney disease. Semin Nephrol 2009; 29(1): 85-93.
8. Frazao JM, Elangovan L, Maung HM et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000; 36(3): 550-561.
9. Hansen D, Brandi L, Rasmussen K. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. BMC Nephrol 2009; 10: 28.
10. Llach F, Keshav G, Goldblat MV et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1, 25-dihydroxyvitamin D2. Am J Kidney Dis. 1998; 32(2 Suppl 2): S48-S54.
11. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2009; (4): CD005633.
12. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007; 147(12): 840-853.
13. Pecovnik-Balon B The effect of peroral calcitriol in small doses on mild secondary hyperparathyroidism in patients on hemodialysis. Am J Nephrol 1995; 15(5): 401-406.
14. Akizawa T, Ohashi Y, Akiba T et al. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 2004; 8(6): 480-491.
15. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24(3): 963-972.
16. Rothman K, Greenland S, Lash T. Modern Epidemiology. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
17. Pearce N What does the odds ratio estimate in a case-control study? Int J Epidemiol. 1993; 22(6): 1189-1192.
18. Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res. 2009; 18(1): 53-65.
19. Tentori F. Trends in medication use and clinical outcomes in twelve countries: results form the Dialysis Outcomes and Practice Patterns Study (DOPPS). Contrib Nephrol 2008; 161: 48-54.